ICTM logo
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
A trial that aims to find the best treatment for people with advanced prostate cancer
What is this study about?

This study is called STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) and looks at the effect of adding new or different treatments to the standard way in which prostate cancer is currently managed.

The standard treatment for prostate cancer involves hormone treatment and may also include chemotherapy and/or radiotherapy.

Prostate cancer needs the male hormone testosterone to grow. Hormone treatments work by stopping testosterone from reaching prostate cancer cells. There are different types of hormone treatments but the most common are injections or implants that work by stopping the testicles making testosterone. Some men will have an operation to remove a part or all of the testicles instead. Your doctor may also discuss chemotherapy or radiotherapy as part of your standard treatment.

This study aims to see if we can improve the way in which prostate cancer is currently managed i.e. by adding new treatments to the standard approach, can we enable men to live longer; or, by modifying the type of hormone therapy, live at least as long and enjoy a better quality of life.

Who is included?

Men with newly diagnosed advanced prostate cancer, or with relapsing prostate cancer.

Contact details

When is it taking place?

Now until around 2026. As new trial arms are added in the future, the end date will be extended.

Where is it taking place?

Hospitals throughout the UK and Switzerland.

Who is funding the study?

The trial is mainly funded by the charity Cancer Research UK with extra support from six pharmaceutical companies: Pfizer, Sanofi-Aventis, Novartis, Janssen, Astellas and Clovis.

Further information

Type of study:
Randomised trial
Open to recruitment
Study start date:
01 October 2005
Also included in this study:
  • Health economics
  • Quality of life outcomes
  • Consumer involvement
  • NHS information centre flagging

Related Publications

Sydes, M. R., Spears, M. R., Mason, M. D., Clarke, N. W., Dearnaley, D. P., de Bono, J. S., Attard, G., Chowdhury, S., Cross, B., Gillessen, S., Malik, Z., Jones, R., Parker, C., Ritchie, A. W. S., Russell, J. M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D., Hughes, R., McLaren, D., Lester, J., Nikapota, A., O'Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S. M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M. K. B., James, N. .

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncolology. 2018.

Spears, M.R., James, N.D., Sydes, M.

'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial. Annals of Oncolology. 2017; 28:2327-2330

Gilson, C., Chowdhury, S., Parmar, M.K.B., Sydes, M.R., Stampede Investigato.

Incorporating biomarker stratification into STAMPEDE: an adaptive multi-arm, multi-stage trial platform. Clinical Oncology Journal (Royal College of Radiologists). 2017; 29:778-786

Gillessen, S., Gilson, C., James, N., Adler, A., Sydes, M., Clarke, N., on behalf of the STAMPEDE Trial Management Grou.

Repurposing Metformin as therapy for prostate cancer within the STAMPEDE trial platform. European Urology. 2016; 70:906-908

James, N.D., Sydes, M.R., Clarke, N.W., Ritchie, A.W., Parmar, M.

Response to 'High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront Docetaxel chemotherapy in usual clinical practice', by Tanguay et al. Clinical Oncology. 2016; 28:666-7